Drugs / ARQ-252
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT04378569 Comparator | Apr 2020 → Feb 2021 | — | Arcutis Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04811131 Comparator | Mar → Aug 2021 | vitiligo | Arcutis Biotherapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-07-01 | Arcutis Biotherapeutics, Inc. | Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo arcutis.com ↗ |
| 2021-03-18 | Arcutis Biotherapeutics, Inc. | Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo arcutis.com ↗ |
| 2020-10-26 | Arcutis Biotherapeutics, Inc. | Arcutis Completes Enrollment in Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema arcutis.com ↗ |
| 2020-07-13 | Arcutis Biotherapeutics, Inc. | Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema arcutis.com ↗ |
| 2020-04-21 | Arcutis Biotherapeutics, Inc. | Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema arcutis.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARQ-252 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04811131 ↗ |